The state of systemic oxidative stress during Parkinson’s disease View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-10

AUTHORS

T. N. Fedorova, A. A. Logvinenko, V. V. Poleshchuk, S. N. Illarioshkin

ABSTRACT

The development of oxidative stress is considered as one of the key molecular mechanisms that lead to the death of dopamine-producing neurons in Parkinson’s disease (PD). Here, we characterized the oxidative status (OS) of patients depending on the severity of the disease, the time course of the disease, and treatment with antiparkinsonian drugs. The OS was evaluated using Fe2+-induced chemiluminescence of serum lipoproteins (LPs) on the basis of informative parameters, including preformed lipid hydroperoxides, the maximum intensity of lipid peroxidation (LPO) and LP resistance to oxidation, due to the activity of the endogenous antioxidant system. In all patients, regardless of the disease stage (second, third, or fourth), we observed a comparable unidirectional increase in the level of lipid hydroperoxides and maximum intensity of (LPO). However, the activity of the endogenous antioxidant system decreased proportionally to the disease severity: second stage > third stage > fourth stage. In patients at the second and third stages of the disease who were treated with antiparkinsonian drugs we found a disruption of the OS in comparison with untreated patients of the same stage. In general, the deterioration of the OS in patients at the second and third stages of the disease, which included an increase in the level of lipid hydroperoxides and the maximum intensity of LPO, was detected in both patients receiving levodopa at a daily dose of more than 300 mg and in patients treated with drugs that did not contain levodopa. The decrease in the activity of the endogenous antioxidant system in these patients did not depend on the method of treatment and the dose of levodopa. The duration of treatment (up to 5 years) did not influence the OS of patients at the second and third stages of the disease. These data confirm the concept of the significance of oxidative stress in the pathogenesis of PD and indicate the advisability of using antioxidant drugs in complex therapy of PD. More... »

PAGES

340-345

Identifiers

URI

http://scigraph.springernature.com/pub.10.1134/s1819712417040031

DOI

http://dx.doi.org/10.1134/s1819712417040031

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1095858628


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1109", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Neurosciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Volokolamskoe shosse 80, 125367, Moscow, Russia", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Research Center of Neurology, Moscow, Russia", 
            "Volokolamskoe shosse 80, 125367, Moscow, Russia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fedorova", 
        "givenName": "T. N.", 
        "id": "sg:person.01301472316.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301472316.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Center of Neurology, Moscow, Russia", 
          "id": "http://www.grid.ac/institutes/grid.465332.5", 
          "name": [
            "Research Center of Neurology, Moscow, Russia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Logvinenko", 
        "givenName": "A. A.", 
        "id": "sg:person.0720220637.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720220637.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Center of Neurology, Moscow, Russia", 
          "id": "http://www.grid.ac/institutes/grid.465332.5", 
          "name": [
            "Research Center of Neurology, Moscow, Russia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Poleshchuk", 
        "givenName": "V. V.", 
        "id": "sg:person.013003057724.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013003057724.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Center of Neurology, Moscow, Russia", 
          "id": "http://www.grid.ac/institutes/grid.465332.5", 
          "name": [
            "Research Center of Neurology, Moscow, Russia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Illarioshkin", 
        "givenName": "S. N.", 
        "id": "sg:person.07612205054.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07612205054.47"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s007020170003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037872457", 
          "https://doi.org/10.1007/s007020170003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12640-014-9495-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018914601", 
          "https://doi.org/10.1007/s12640-014-9495-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11064-008-9656-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006022157", 
          "https://doi.org/10.1007/s11064-008-9656-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1134/s1819712411020073", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043282239", 
          "https://doi.org/10.1134/s1819712411020073"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd3430", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025145286", 
          "https://doi.org/10.1038/nrd3430"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-10", 
    "datePublishedReg": "2017-10-01", 
    "description": "The development of oxidative stress is considered as one of the key molecular mechanisms that lead to the death of dopamine-producing neurons in Parkinson\u2019s disease (PD). Here, we characterized the oxidative status (OS) of patients depending on the severity of the disease, the time course of the disease, and treatment with antiparkinsonian drugs. The OS was evaluated using Fe2+-induced chemiluminescence of serum lipoproteins (LPs) on the basis of informative parameters, including preformed lipid hydroperoxides, the maximum intensity of lipid peroxidation (LPO) and LP resistance to oxidation, due to the activity of the endogenous antioxidant system. In all patients, regardless of the disease stage (second, third, or fourth), we observed a comparable unidirectional increase in the level of lipid hydroperoxides and maximum intensity of (LPO). However, the activity of the endogenous antioxidant system decreased proportionally to the disease severity: second stage > third stage > fourth stage. In patients at the second and third stages of the disease who were treated with antiparkinsonian drugs we found a disruption of the OS in comparison with untreated patients of the same stage. In general, the deterioration of the OS in patients at the second and third stages of the disease, which included an increase in the level of lipid hydroperoxides and the maximum intensity of LPO, was detected in both patients receiving levodopa at a daily dose of more than 300 mg and in patients treated with drugs that did not contain levodopa. The decrease in the activity of the endogenous antioxidant system in these patients did not depend on the method of treatment and the dose of levodopa. The duration of treatment (up to 5 years) did not influence the OS of patients at the second and third stages of the disease. These data confirm the concept of the significance of oxidative stress in the pathogenesis of PD and indicate the advisability of using antioxidant drugs in complex therapy of PD.", 
    "genre": "article", 
    "id": "sg:pub.10.1134/s1819712417040031", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1038858", 
        "issn": [
          "1819-7124", 
          "1819-7132"
        ], 
        "name": "Neurochemical Journal", 
        "publisher": "Pleiades Publishing", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "11"
      }
    ], 
    "keywords": [
      "endogenous antioxidant system", 
      "Parkinson's disease", 
      "oxidative status", 
      "antiparkinsonian drugs", 
      "lipid peroxidation", 
      "oxidative stress", 
      "dopamine-producing neurons", 
      "pathogenesis of PD", 
      "dose of levodopa", 
      "lipid hydroperoxides", 
      "OS of patients", 
      "systemic oxidative stress", 
      "duration of treatment", 
      "method of treatment", 
      "antioxidant system", 
      "untreated patients", 
      "daily dose", 
      "disease stage", 
      "complex therapy", 
      "patients", 
      "serum lipoproteins", 
      "disease severity", 
      "key molecular mechanisms", 
      "antioxidant drugs", 
      "disease", 
      "levodopa", 
      "drugs", 
      "time course", 
      "treatment", 
      "dose", 
      "severity", 
      "lipoproteins", 
      "molecular mechanisms", 
      "same stage", 
      "therapy", 
      "pathogenesis", 
      "neurons", 
      "activity", 
      "death", 
      "peroxidation", 
      "levels", 
      "third stage", 
      "duration", 
      "increase", 
      "stage", 
      "status", 
      "stress", 
      "course", 
      "deterioration", 
      "disruption", 
      "hydroperoxide", 
      "decrease", 
      "significance", 
      "advisability", 
      "chemiluminescence", 
      "resistance", 
      "mechanism", 
      "intensity", 
      "informative parameters", 
      "unidirectional increase", 
      "data", 
      "development", 
      "fourth stage", 
      "maximum intensity", 
      "comparison", 
      "second stage", 
      "system", 
      "basis", 
      "method", 
      "parameters", 
      "state", 
      "oxidation", 
      "concept", 
      "Fe2", 
      "LP resistance", 
      "comparable unidirectional increase"
    ], 
    "name": "The state of systemic oxidative stress during Parkinson\u2019s disease", 
    "pagination": "340-345", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1095858628"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1134/s1819712417040031"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1134/s1819712417040031", 
      "https://app.dimensions.ai/details/publication/pub.1095858628"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:40", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_744.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1134/s1819712417040031"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1134/s1819712417040031'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1134/s1819712417040031'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1134/s1819712417040031'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1134/s1819712417040031'


 

This table displays all metadata directly associated to this object as RDF triples.

179 TRIPLES      22 PREDICATES      107 URIs      94 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1134/s1819712417040031 schema:about anzsrc-for:11
2 anzsrc-for:1109
3 schema:author N6b7679aad11b480a88f55e6b49ae5f9a
4 schema:citation sg:pub.10.1007/s007020170003
5 sg:pub.10.1007/s11064-008-9656-2
6 sg:pub.10.1007/s12640-014-9495-7
7 sg:pub.10.1038/nrd3430
8 sg:pub.10.1134/s1819712411020073
9 schema:datePublished 2017-10
10 schema:datePublishedReg 2017-10-01
11 schema:description The development of oxidative stress is considered as one of the key molecular mechanisms that lead to the death of dopamine-producing neurons in Parkinson’s disease (PD). Here, we characterized the oxidative status (OS) of patients depending on the severity of the disease, the time course of the disease, and treatment with antiparkinsonian drugs. The OS was evaluated using Fe2+-induced chemiluminescence of serum lipoproteins (LPs) on the basis of informative parameters, including preformed lipid hydroperoxides, the maximum intensity of lipid peroxidation (LPO) and LP resistance to oxidation, due to the activity of the endogenous antioxidant system. In all patients, regardless of the disease stage (second, third, or fourth), we observed a comparable unidirectional increase in the level of lipid hydroperoxides and maximum intensity of (LPO). However, the activity of the endogenous antioxidant system decreased proportionally to the disease severity: second stage > third stage > fourth stage. In patients at the second and third stages of the disease who were treated with antiparkinsonian drugs we found a disruption of the OS in comparison with untreated patients of the same stage. In general, the deterioration of the OS in patients at the second and third stages of the disease, which included an increase in the level of lipid hydroperoxides and the maximum intensity of LPO, was detected in both patients receiving levodopa at a daily dose of more than 300 mg and in patients treated with drugs that did not contain levodopa. The decrease in the activity of the endogenous antioxidant system in these patients did not depend on the method of treatment and the dose of levodopa. The duration of treatment (up to 5 years) did not influence the OS of patients at the second and third stages of the disease. These data confirm the concept of the significance of oxidative stress in the pathogenesis of PD and indicate the advisability of using antioxidant drugs in complex therapy of PD.
12 schema:genre article
13 schema:inLanguage en
14 schema:isAccessibleForFree false
15 schema:isPartOf N2a1de7a1e1ea40ba96140648cc665b15
16 N49d77a9e26b74f8489a87212d76f3244
17 sg:journal.1038858
18 schema:keywords Fe2
19 LP resistance
20 OS of patients
21 Parkinson's disease
22 activity
23 advisability
24 antioxidant drugs
25 antioxidant system
26 antiparkinsonian drugs
27 basis
28 chemiluminescence
29 comparable unidirectional increase
30 comparison
31 complex therapy
32 concept
33 course
34 daily dose
35 data
36 death
37 decrease
38 deterioration
39 development
40 disease
41 disease severity
42 disease stage
43 disruption
44 dopamine-producing neurons
45 dose
46 dose of levodopa
47 drugs
48 duration
49 duration of treatment
50 endogenous antioxidant system
51 fourth stage
52 hydroperoxide
53 increase
54 informative parameters
55 intensity
56 key molecular mechanisms
57 levels
58 levodopa
59 lipid hydroperoxides
60 lipid peroxidation
61 lipoproteins
62 maximum intensity
63 mechanism
64 method
65 method of treatment
66 molecular mechanisms
67 neurons
68 oxidation
69 oxidative status
70 oxidative stress
71 parameters
72 pathogenesis
73 pathogenesis of PD
74 patients
75 peroxidation
76 resistance
77 same stage
78 second stage
79 serum lipoproteins
80 severity
81 significance
82 stage
83 state
84 status
85 stress
86 system
87 systemic oxidative stress
88 therapy
89 third stage
90 time course
91 treatment
92 unidirectional increase
93 untreated patients
94 schema:name The state of systemic oxidative stress during Parkinson’s disease
95 schema:pagination 340-345
96 schema:productId N3186494aeb5f4f49b13fcc02b1c820e9
97 Nd318ef9743474c87940ce2cac39ed958
98 schema:sameAs https://app.dimensions.ai/details/publication/pub.1095858628
99 https://doi.org/10.1134/s1819712417040031
100 schema:sdDatePublished 2021-12-01T19:40
101 schema:sdLicense https://scigraph.springernature.com/explorer/license/
102 schema:sdPublisher N6b2f622bd22744ee9f0257190adaabe0
103 schema:url https://doi.org/10.1134/s1819712417040031
104 sgo:license sg:explorer/license/
105 sgo:sdDataset articles
106 rdf:type schema:ScholarlyArticle
107 N2a1de7a1e1ea40ba96140648cc665b15 schema:issueNumber 4
108 rdf:type schema:PublicationIssue
109 N3186494aeb5f4f49b13fcc02b1c820e9 schema:name doi
110 schema:value 10.1134/s1819712417040031
111 rdf:type schema:PropertyValue
112 N3bc1eedfb1094395bc5cb7db5c10a55d rdf:first sg:person.0720220637.86
113 rdf:rest Ncd229d1a3d0e466baadea174891576cc
114 N49d77a9e26b74f8489a87212d76f3244 schema:volumeNumber 11
115 rdf:type schema:PublicationVolume
116 N6b2f622bd22744ee9f0257190adaabe0 schema:name Springer Nature - SN SciGraph project
117 rdf:type schema:Organization
118 N6b7679aad11b480a88f55e6b49ae5f9a rdf:first sg:person.01301472316.58
119 rdf:rest N3bc1eedfb1094395bc5cb7db5c10a55d
120 Ncd229d1a3d0e466baadea174891576cc rdf:first sg:person.013003057724.66
121 rdf:rest Nddb4e08115034d61a0b537744ce40f1f
122 Nd318ef9743474c87940ce2cac39ed958 schema:name dimensions_id
123 schema:value pub.1095858628
124 rdf:type schema:PropertyValue
125 Nddb4e08115034d61a0b537744ce40f1f rdf:first sg:person.07612205054.47
126 rdf:rest rdf:nil
127 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
128 schema:name Medical and Health Sciences
129 rdf:type schema:DefinedTerm
130 anzsrc-for:1109 schema:inDefinedTermSet anzsrc-for:
131 schema:name Neurosciences
132 rdf:type schema:DefinedTerm
133 sg:journal.1038858 schema:issn 1819-7124
134 1819-7132
135 schema:name Neurochemical Journal
136 schema:publisher Pleiades Publishing
137 rdf:type schema:Periodical
138 sg:person.013003057724.66 schema:affiliation grid-institutes:grid.465332.5
139 schema:familyName Poleshchuk
140 schema:givenName V. V.
141 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013003057724.66
142 rdf:type schema:Person
143 sg:person.01301472316.58 schema:affiliation grid-institutes:None
144 schema:familyName Fedorova
145 schema:givenName T. N.
146 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301472316.58
147 rdf:type schema:Person
148 sg:person.0720220637.86 schema:affiliation grid-institutes:grid.465332.5
149 schema:familyName Logvinenko
150 schema:givenName A. A.
151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720220637.86
152 rdf:type schema:Person
153 sg:person.07612205054.47 schema:affiliation grid-institutes:grid.465332.5
154 schema:familyName Illarioshkin
155 schema:givenName S. N.
156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07612205054.47
157 rdf:type schema:Person
158 sg:pub.10.1007/s007020170003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037872457
159 https://doi.org/10.1007/s007020170003
160 rdf:type schema:CreativeWork
161 sg:pub.10.1007/s11064-008-9656-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006022157
162 https://doi.org/10.1007/s11064-008-9656-2
163 rdf:type schema:CreativeWork
164 sg:pub.10.1007/s12640-014-9495-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018914601
165 https://doi.org/10.1007/s12640-014-9495-7
166 rdf:type schema:CreativeWork
167 sg:pub.10.1038/nrd3430 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025145286
168 https://doi.org/10.1038/nrd3430
169 rdf:type schema:CreativeWork
170 sg:pub.10.1134/s1819712411020073 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043282239
171 https://doi.org/10.1134/s1819712411020073
172 rdf:type schema:CreativeWork
173 grid-institutes:None schema:alternateName Volokolamskoe shosse 80, 125367, Moscow, Russia
174 schema:name Research Center of Neurology, Moscow, Russia
175 Volokolamskoe shosse 80, 125367, Moscow, Russia
176 rdf:type schema:Organization
177 grid-institutes:grid.465332.5 schema:alternateName Research Center of Neurology, Moscow, Russia
178 schema:name Research Center of Neurology, Moscow, Russia
179 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...